ALLMedicine™ Hyperbilirubinemia Center - News
Jan 11th, 2008 - Action Points Explain to interested patients that the study found that predischarge bilirubin levels and gestational age predict which infants are at high risk of developing hyperbilirubinemia serious enough to warrant treatment. Point out that the cost-benefit balance of a screening program based on this model has not been calculated. PHILADELPHIA, Jan. 11 -- Newborns at risk for severe hyperb...
Jun 9th, 2017 - Action Points Enasidenib is effective in inducing remission in patients with relapsed or treatment-resistant acute myeloid leukemia (AML), and an isocitrate dehydrogenase-2 (IDH2) gene mutation. Note that enasidenib treatment was generally well-tolerated, and 24% of patients had treatment-related serious adverse events, including IDH differentiation syndrome, leukocytosis, tumor lysis syndrome,...
May 4th, 2006 - Action Points Advise parents that this study suggests hyperbilirubinemia can be effectively treated with phototherapy and does not result in long-term neurological damage in the vast majority of cases. Be aware that the American Academy of Pediatrics recommends that treatment be given to newborns to keep total serum bilirubin levels from exceeding 25 mg/dL. SAN FRANCISCO, May 4 — The risk of a ...
Mary Ann Moon
Maternal glucose levels that were high but below the diagnostic threshold for gestational diabetes were strongly associated with high fetal insulin levels and birth weights in an international study of 23,316 pregnant women. There were also weaker—but still significant—associations between maternal hyperglycemia that fell short of overt gestational diabetes and a host of neonatal problems: hypo.
Mary Ann Moon
Treating mild gestational diabetes lowered the risks of fetal overgrowth, shoulder dystocia, cesarean delivery, and gestational hypertension, as well as decreasing maternal weight gain, based on a study of almost 1,000 women. However, treating mild gestational diabetes did not improve the composite primary outcome of neonatal mortality, hypoglycemia, hyperbilirubinemia, hyperinsulinemia, and bi.
Family Practice News; Mary Ann Moon
Treating mild gestational diabetes lowered the risks of fetal overgrowth, shoulder dystocia, cesarean delivery, and gestational hypertension, as well as decreasing maternal weight gain, according to a report in almost 1,000 women. However, treating mild gestational diabetes did not improve the composite primary outcome of neonatal mortality, hypoglycemia, hyperbilirubinemia, hyperinsulinemia, a.
Jane Salodof MacNeil
SAN FRANCISCO — Fluconazole prophylaxis reduced fungal infections and mortality in very low-birth-weight infants at two neonatal intensive care units in retrospective studies that were presented during the annual meeting of the Pediatric Academic Societies. Incidence of invasive candidiasis in very low-birth-weight (VLBW) infants went from 6.
Family Practice News; Elizabeth Mechcatie
Reports of severe liver injuries—including one fatality—associated with Hydroxycut brand dietary supplements have prompted a nationwide product recall, the Food and Drug Administration announced last month. The products are marketed as weight-loss aids, energy-enhancers, low-carbohydrate diet aids, and diuretics.
Family Practice News; Mary Ann Moon
Maternal glucose levels that were high but below the diagnostic threshold for gestational diabetes were strongly associated with high fetal insulin levels and birth weights in a large international study. There were also weaker—but still significant—associations between maternal hyperglycemia that fell short of overt gestational diabetes, as well as a host of neonatal problems that included hyp.
May 2nd, 2018 - WASHINGTON -- Just one dose of a drug called stannsoporfin significantly reduced bilirubin levels in newborns with severe hyperbilirubinemia, but at the potential cost of long-term neurological risk, according to an FDA briefing document prepared for a Thursday advisory committee meeting. The FDA's Gastrointestinal Drugs Advisory Committee and the Pediatric Advisory Committee will meet jointly ...
Dec 23rd, 2019 - Currently, the multisite MOMPOD trial (Medical Optimization of Management of T2DM Complicating Pregnancy) is randomizing 950 women to insulin plus 1,000 mg metformin twice daily or insulin plus placebo. The primary outcome of the trial is a composite of pregnancy loss, preterm birth, birth injury, neonatal hypoglycemia, or hyperbilirubinemia.
Jan 25th, 2011 - Neonates who are delivered at 36-38 weeks’ gestation after fetal lung maturity is confirmed have nearly double the risk of adverse outcomes, compared with neonates delivered at 39 or 40 weeks, a large retrospective cohort study has shown. The mean birth weight in 459 neonates with confirmed lung maturity who were delivered at 36-38 weeks’ gestation was 3,017 g, compared with 3,362 g in 13,339 n.
Apr 18th, 2018 - The most common overall toxicities included febrile neutropenia in 70% of patients; transaminitis (including one grade 3 case) in 50%, hyperbilirubinemia in 35%, and fatigue, increased alkaline phosphatase, and rash in 25% each. Novel therapies for relapsed/refractory AML are urgently needed, and these early results demonstrated the safety and feasibility of adding pembrolizumab after HiDAC che.
Clinical Endocrinology News; Amy Karon
May 2nd, 2018 - A randomized, multicenter trial failed to find glyburide noninferior to insulin for treatment of gestational diabetes, investigators reported. The composite rate of macrosomia, neonatal hypoglycemia, and hyperbilirubinemia was 27.
Jan 23rd, 2015 - Differences in adverse events included lower rates of hepatobiliary disorders, including hyperbilirubinemia, abnormal hepatic function, and jaundice (9% vs. 16%); skin and subcutaneous tissue disorders, including rash, erythema, and drug eruption (34% vs 43%) associated with isavuconazonium, compared with voriconazole.
Family Practice News;
Oct 25th, 2013 - In phase III studies, fatigue, headache, and influenzalike illness, associated with PR, were the most common adverse events. The only deaths reported were in three patients treated with simeprevir after they stopped taking the drug, but were not considered related to the drug.
MDedge Family Medicine;
Jan 28th, 2019 - The US Preventative Services Task Force, however, found insufficient evidence to recommend universal screening for infants ≥35 weeks’ gestation. 27 The main rationale for their “I” recommendation was that although screening can identify infants at risk of developing severe hyperbilirubinemia, there is no clear evidence that identifying and treating elevated bilirubin levels results in the preven.
Fetal Surveillance for RhD Alloimmunization RhD alloimmunization occurs because RhIG was not administered, the dose was inadequate, or, despite RhIG administration, maternal production of anti-D antibody occurs. RhD alloimmunization exposes future pregnancies with RhD-positive fetuses to hemolytic disease of the fetus and newborn. Consequences of hemolytic disease of the fetus and newborn may b...
Potential Adverse Effects of Delayed Cord Clamping It has been postulated that delayed cord clamping may increase rates of hyperbilirubinemia, polycythemia, and transient tachypnea in the newborn or maternal hemorrhage. However, delayed cord clamping has never been proven to increase the rate of neonatal symptomatic disease or maternal blood loss.[3,6,9] Polycythemia Polycythemia is defined as ...
Mar 1st, 2020 - Some communications among a patient's healthcare team may not be as direct as one would prefer, but they may still trigger a duty on the recipient to follow up. Dr P, a general pediatrician, was called to attend a vaginal delivery of a newborn with a history of three fetal transfusion surgeries. Dr P ordered for his newborn patient a transcutaneous bilirubin test, and when that test revealed hy...